Abstract The complement cascade is a critical mediator of the inflammatory response following cerebral ischemia. Recent work has demonstrated that genetic deficiency of mannose-binding lectin (MBL) ameliorates reperfusion injury and improves outcome in the acute phase of stroke. The present study sought to further delineate the pathogenic role of MBL in stroke and to examine whether the neuroprotection associated with MBL deficiency is sustained beyond the acute phase. We hypothesized that genetic MBL deficiency would suppress complement activation and ameliorate reperfusion injury in the acute phase, but that persistent inhibition of complement into the subacute phase would serve to abrogate this neuroprotective effect. The time course and localization of post-ischemic cerebral MBL and C3 deposition were characterized using both Western blot and immunohistochemistry. MBL-a/c null (MBL-KO) mice subjected to transient middle cerebral artery occlusion were then employed to investigate the histologic injury and functional outcome associated with genetic MBL deletion at both 24 h and 7 days. MBL-a/c rapidly deposit on ischemic endothelium and trigger downstream complement activation in the acute phase. Genetic deficiency of MBL abrogates C3 cleavage as well as the subacute accumulation of mononuclear cells in the ischemic region. Although MBL-KO mice demonstrate significantly improved outcome at 24 h, the neuroprotective effect associated with genetic MBL deletion is not sustained.
Introduction
Inflammation promotes acute neuronal injury following reperfusion of an occluded cerebral blood vessel and serves to limit the therapeutic effectiveness of both pharmacologic and mechanical reperfusion strategies [1, 2] . The complement cascade, a primary component of the ischemic inflammatory response, is central to the initiation and propagation of this cerebral reperfusion injury [3] [4] [5] [6] [7] [8] . Both genetic and pharmacologic strategies have been employed to ameliorate experimental cerebral injury in the acute phase by directly inhibiting complement component C3 or by antagonizing the binding of the C3a anaphylatoxin to its cognate receptor [5, 9] . However, investigation into the proximal pathway mechanisms responsible for the initiation of complement activation early following ischemic induction has received comparatively less attention [9] .
The lectin pathway of the complement cascade classically begins with mannose-binding lectin (MBL)-mediated recognition of terminal oligosaccharides presented on the surface of a target cell. This incites a conformational change in the MBL molecule, activating the MBL-associated serine proteases (MASPs), followed by MASP-mediated cleavage of complement components C4 and C2 to form the C3 convertase [10] . Emerging evidence suggests that the lectin pathway is central to the propagation of ischemiareperfusion injury across a variety of tissues [11, 12] . Additionally, two groups have recently published studies analyzing a role for MBL in stroke. The authors of these studies utilized mice genetically deficient in MBL (MBL-KO) subjected to middle cerebral artery occlusion (MCAO) to implicate MBL in the pathogenesis of cerebral reperfusion injury [13, 14] .
Although this work suggests that MBL contributes to inflammatory cerebral injury in the acute phase of stroke, adequate assessment of a candidate therapeutic target in translational stroke research must include an assessment of delayed functional outcome. This is particularly relevant for anti-inflammatory strategies, as inflammation contributes to the process of post-ischemic repair at delayed time points [15, 16] . Additionally, complement activation itself has been postulated to play a direct role in stroke recovery, as deposition of a variety of complement components, including MBL, facilitates the clearance of damaged cells and debris in the subacute to chronic phases of neurodegeneration [17] . Furthermore, recent work suggests that complement may promote both basal and ischemia-induced neurogenesis [18] . These data argue that suppression of complement beyond the acute postischemic period may actually impair endogenous neurorestorative processes.
In order to further elucidate the role of complement activation in cerebral ischemia/reperfusion, we set out to rigorously characterize the activation of the MBL pathway in reperfused stroke, focusing on both the acute and subacute phases of stroke recovery. We began by examining the time course of complement activation for 7 days following reperfused MCAO in mice. MBL-KO mice subjected to transient MCAO were then employed to evaluate the effect of genetic MBL deficiency on downstream complement cleavage, as well as histologic and functional injury, at both 24 h and 7 days post-reperfusion. We hypothesized that genetic MBL deficiency would suppress complement activation and ameliorate reperfusion injury in the acute phase, but that persistent inhibition of complement into the subacute phase would serve to abrogate this neuroprotective effect.
Materials and Methods
All experiments were approved by the Columbia University Institutional Animal Care and Use Committee. All surgical manipulations, functional evaluation, and biochemical assessments were performed by a blinded investigator, and random allocation of animals in each experimental cohort was performed throughout these experiments.
Mice
Adult male MBL-null mice (B6.129S4-Mbl1 tm1Kata Mbl2 tm1Kata /J) (8-12 weeks old, 23-26 g) were obtained from Jackson Laboratories (Bar Harbor, ME, USA). These mice were backcrossed into C57Bl/6J background for seven generations, and age/weight-matched C57Bl/6J mice were used as wild-type controls. Animals were housed in certified barrier facilities with free access to food and water.
Murine Model of MCAO Mice were anesthetized with 1.5% isoflurane delivered in a 70% N 2 O/30% O 2 mixture. MCAO was achieved by advancing a silicon-coated 7-0 nylon monofilament to the MCA origin, with reperfusion achieved by withdrawing the filament after 60 min [5, 19] . For all animals, transcranial cerebral blood flow (CBF) was measured continuously using laser Doppler flowmetry beginning pre-occlusion and extending 15 min post-reperfusion (Periflux System 5000; Perimed, Stockholm, Sweden) [19, 20] . Animals were included if occlusion suppressed blood flow to <30% of baseline and if reperfusion resulted in prompt resumption of CBF. Core temperature was maintained at 37.0±0.1°C using a Digi-Sense temperature controller (Cole-Parmer, Vernon Hills, IL, USA) via a heat-lamp coupled with a thermistor rectal-probe (Model 400, Yellow Springs Instruments Co., Yellow Springs, OH, USA). Postoperatively, an animal intensive care unit (Lyon Electric Company, Chula Vista, CA, USA) was employed to maintain a temperature of 37°C for a total of 150 min. Animals were sacrificed at 0 and 24 h and 7 days, and brains were harvested and prepared for histology as detailed below. Delayed functional evaluation was performed in animals undergoing 30 min of MCAO. Sham animals underwent surgical exposure and filament insertion without occlusion.
Antibodies and Reagents
Primary antibodies used for Western blot include rat anti-mouse monoclonal C3a antibody (BD-Pharmingen, San Diego, CA, USA) (1:500 dilution), rabbit polyclonal anti-mouse IgM antibody (Novus Biologicals, Littleton, CO, USA) (1:1,000), goat anti-mouse MBL-1 antibody (R&D Systems, Minneapolis, MN, USA) (1:1,000), goat anti-mouse MBL-2 antibody (R&D Systems) (1:1,000), rat anti-mouse monoclonal CD68 (AbD Serotec, Raleigh, NC, USA) (1:2,000), rabbit polyclonal anti-mouse factor B antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1:1,000), and goat polyclonal anti-mouse C1q-A antibody (Santa Cruz Biotechnology) (1:1,000 
Histologic Analyses
Following transcardiac PBS perfusion, brains were harvested, fixed in 4% paraformaldehyde, and cryoprotected. Brains were frozen in optimal cutting temperature compound (Sakura Finetek US, Torrance, CA, USA) (−80°C) and cut by cryostat into 20 μm coronal sections. For immunofluorescence, sections were blocked with the secondary antibody-appropriate serum (10% donkey or goat serum) with PBS containing 0.2% Triton X-100 for 30 min at room temperature. Sections were incubated in primary antibodies diluted in PBS containing 0.2% Triton X-100 overnight at 4°C. Sections were then washed and incubated with the corresponding secondary antibodies Alexa Fluor 488, 594, or 647 (Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature. Neurotrace 640/660 fluorescent Nissl (Invitrogen) was used for counterstaining. Sections were then mounted on slides in Vectashield (Vector Laboratories, Burlingame, CA, USA) and visualized using a Bio-Rad 2000 confocal laser-scanning device (Bio-Rad, Hercules, CA, USA) with a Nikon E800 microscope (Nikon, San Diego, CA, USA).
Western Blot
For analysis of protein profiles by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), mice were killed and immediately perfused intracardially with 2 ml ice-cold saline prior to brain harvest. The ischemic and contralateral non-ischemic brain tissues were excised and homogenized in lysis buffer (20 mM Tris-HCl pH 7.5, 1% Triton, 150 mM NaCl, 1 mM EDTA, Halt™ Proteinase Inhibitor Cocktail). The samples were electrophoresed under reduced conditions on 4-12% gradient SDS-PAGE gels. The proteins were transferred onto nitrocellulose membrane and hybridized with specific primary antibodies. After incubation with appropriate horseradish peroxidaseconjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), the signal was detected using chemiluminescence (Supersignal West Pico Chemiluminescent Substrate; Pierce, Rockford, IL, USA). The relative band intensity was quantified using ImageJ (version 1.43, NIH, http://rsb.info.nih.gov/ij) and the results were normalized to both β-actin and contralateral hemisphere expression using the formula: normalized intensity = [(ipsilateral pixel density /ipsilateral β-actin density)/(contralateral pixel density/contralateral β-actin density)].
Infarct Volume Determination
For animals sacrificed at 24 h, mice were euthanized and 1-mm sections of the brain were stained with TTC as previously described [20] . Infarct volumes were calculated by two blinded, independent observers and expressed indirectly to control for hemispheric edema [21] .
For animals sacrificed at 7 days, brains were cryosectioned into coronal sections at 0.5 mm intervals as detailed above. Sections were stained with H&E, and infarct volume was quantified using a standard computer-assisted analysis technique (Image Pro Plus 4.5, Media Cybernetics, Bethesda, MD, USA).
Neurofunctional Assessment
Neurological function was assessed at 24 h using a previously described 28-point scale which assesses both focal and global functional deficits [22] . For delayed functional evaluation at 7 days, an extensive battery was employed including the Morris water maze [23, 24] , open-field [25] , and corner-turn tests [24, 26] .
Navigational memory and learning was evaluated using the Morris water maze [23, 24] . For this test, mice were tested in a pool 80 cm in diameter filled with opaque white water at a depth of 20 cm. The water temperature was maintained at 26°C. The rescue-landing platform (3 cm diameter) was submerged 0.5 cm under the water surface in one of four quadrants. Navigational cues were placed on the walls of the pool and a small flag was placed on the landing platform. The testing began on postoperative day 3 with four consecutive training days. On each of these days, three attempts were given to each mouse to find the platform within 120 s. Each mouse was allowed 20 min to rest between swimming trials. The training session occurred at the same time of the day throughout the training and testing periods. A mouse was placed in the water in the quadrant opposite to the landing. The time (in seconds) spent by each animal to find the platform was recorded. If the mouse failed to locate and climb on the platform within the allotted time, it was gently placed on the platform for 30 s. On postoperative day 7, mice were placed in the same swimming pool without the landing platform for 60 s (probe trial). The time spent in the quadrant where the landing had been previously situated was recorded in a masked fashion. Each animal was afforded only one attempt.
The open-field test was performed on the day of sacrifice to assess spontaneous locomotor activity and exploratory behavior [25] . Mouse behavior was monitored in the open-field apparatus consisting of a square plastic chamber (50×50×25 cm). Animals were allowed to start from one of the four corners, selected randomly by the experimenter. Animal location and animal path length data were collected for 10 min after a 2-min habituation. All movements of each animal in the open-field apparatus were traced and analyzed with commercially available software (Smart Junior, Harvard Apparatus, Holliston, Massachusetts, USA).
Sensorimotor impairment was analyzed using the cornerturn test [24] . For this test, the mouse was allowed to walk down a corridor into a 30°corner. The mouse's choice of turn direction was noted. The number of right and left turns out of ten attempts was recorded. The laterality index (LI) and normalized LI were calculated for each mouse according to the formula: LI=(number of right turns−number of left turns)/(total number of turns) [26] . The LI for the day before surgery (LI BS ) and each of the post-surgery days were calculated and normalized using the formula: normalized LI=(LI+2)/(LI BS +2).
Statistical Analysis
All data are presented as mean ± standard error of the mean. Between-group differences were calculated using two-tailed Student's t test or analysis of variance, with Mann-Whitney and Kruskal-Wallis tests for non-parametric data, as appropriate. All values were considered significant when p<0.05. Statistical analyses were performed using commercially available software (SPSS Statistics 17.0, SPSS Inc., Chicago, IL, USA). (Fig. 1b) . Deposition of IgM occurs rapidly in a similar fashion, but peaks at 7 days (sham 0.95±0.17; 0 h 4.75±2.24; 24 h 3.54±1.17; 7 days 6.92±1.01; p<0.05) (Fig. 1c) . Thus, MBL-a/c and IgM protein deposition occur along a similar time course in the ischemic hemisphere. Immunohistochemistry was also utilized to assess the cellular localization of MBL-a/c and IgM antigen. At 0 h post-reperfusion, MBL-a co-localizes with both IgM and C3 on the endothelial surface of ischemic microvessels (Fig. 2a) . MBL-c demonstrates a similar pattern of early endothelial deposition, including co-localization with IgM and C3 at the same time point (Fig. 2b) . The endothelial localization of the MBL-a/c antigen was confirmed by confocal microscopy (Fig. 2c, d) . In all samples, MBL-a/c expression at the 0-h time point was confined to the ischemic territory and was not observed in non-ischemic ipsilateral territories or in contralateral brain regions (data not shown).
Results

MBL-a/c Deposit in Association with
At 24 h, MBL-a co-localizes with both IgM and C3 on the surface of cells with neuronal morphology in the ischemic region (Fig. 3a) . The neuronal identity of these cells was confirmed by co-staining with MAP-2 (Fig. 3c) . By contrast, MBL-c remained associated with C3 in the perivascular region, but did not bind to neurons (Fig. 3b, d) .
By (Fig. 4a) (Fig. 5a ) relative to D B C A Fig. 3 MBL-a deposits on ischemic neurons at 24 h, whereas MBL-c remains in the perivascular region. a Immunostaining of the ischemic region at 24 h post-reperfusion for MBL-a (blue), C3 (red), IgM (green), and triple stain reveals that MBL-a is observed in association with IgM and triggers cleavage of C3 on cells with the morphologic characteristics of neurons. b Immunostaining of the ischemic region for MBL-c (blue), C3 (red), IgM (green), and triple stain at 24 h post-reperfusion in the same anatomic region reveals that although MBL-c antigen is deposited in association with C3, it is not found on neuronal cells, whereas C3 and IgM co-localize to cells with the morphology of neurons. c Immunostaining for MBL-a (red) and MAP-2 (green) and double staining in the same anatomic region at 24 h unambiguously confirms the neuronal phenotype of these cells. d Further staining in the same region for MBL-a (red), vWF (green), and double stain suggests that MBL-c antigen remains in and around ischemic microvessels at this time point. Merged images for all panels are co-stained with Nissl as a nuclear marker (blue) that of WT mice. Therefore, genetic deletion of MBL attenuates downstream complement activation in the ischemic hemisphere at both acute and subacute time points.
MBL Deletion Suppresses Inflammatory Mononuclear Cell Infiltrate in the Subacute Phase of Stroke Recovery
Mononuclear inflammatory cells (microglia/macrophage) in the ischemic hemisphere were assessed by immunostaining and Western blot for the cell surface protein CD68. At 24 h, no significant increase in CD68 immunopositivity was observed by Western Blot, and immunostaining did not reveal significant CD68 antigen in the ischemic territory (data not shown). In contrast, Western blot performed on brain sections obtained from WT and MBL-KO animals sacrificed at 7 days revealed a significant suppression of CD68 immunopositivity in the ischemic hemisphere of KO animals [60.37±50.01 (n=3) vs. 638.2±138.0 (n=5); p=0.04] (Fig. 5b) . This was supported by immunostaining studies revealing significantly decreased numbers of CD68-positive cells in the region of the infarct in MBL-KO mice (Fig. 5c ) relative to the corresponding anatomic regions of WT control brain (Fig. 5d) . Therefore, genetic deletion of MBL suppresses the accumulation of mononuclear inflammatory cells in the ischemic hemisphere in the subacute post-stroke period.
Genetic Deletion of MBL Confers Robust Neuroprotection at 24 h but Not 7 Days Following MCAO
The functional effect of genetic MBL deletion was assessed by subjecting MBL-KO mice and their wild-type controls to transient MCAO. As variations in cerebrovascular anatomy between strains is known to result in differential susceptibility to cerebral ischemia in mice [27] , we stained the circle of Willis by infusing a 1% solution of methylene blue in saline in mice deficient in MBL as well as WT mice (n=3 per cohort) [28] . We did not observe any gross differences in cerebrovascular anatomy between these cohorts of mice (Fig. 6) .
At (Fig. 7a) . There was no difference in rates of mortality between these cohorts (p=NS). When mice were survived to 7 days, however, infarction volume was not significantly improved in MBL-KO mice [31.4±4.3 mm 3 (n=12) vs. 39.5 ±6.9 mm 3 (n=10), p=0.54] (Fig. 7b ). The mortality rates at 7 days also did not differ between the cohorts (p=NS). Additionally, no functional benefit for genetic MBL deletion was observed at 7 days on any functional tests employed (Fig. 7c) . Thus, the acute neuroprotection afforded by genetic MBL deficiency is not sustained when assessed at 7 days.
Discussion
The present study demonstrates that the MBL pathway serves as a critical mechanism of post-ischemic complement activation in the early post-stroke period. Following transient MCAO, MBL-a and MBL-c deposit together with C3 and IgM on ischemic endothelium. By 24 h, only MBLa associates with C3 and IgM on neurons in the region of the infarct. In accord with prior work [13] , genetic deficiency of MBL suppresses cleavage of C3 and confers robust neuroprotection when assessed at 24 h. When outcome was assessed at 7 days, however, this neuroprotective effect was not sustained. Therefore, while the MBL pathway is essential to deleterious complementmediated ischemic injury in the acute phase of stroke, continued suppression of MBL into the subacute period abrogates this neuroprotection.
Few studies have focused on elucidating the proximal mechanisms responsible for the assembly of the C3 convertase following cerebral ischemia [5, 9, 29] . Multiple independent groups have examined the contribution of the classical pathway to stroke injury and have concluded that complement-mediated post-ischemic injury occurs independent of the classical pathway [9, 30] . In contrast, no study has been published in which selective inhibition of the alternative pathway has been employed in the setting of stroke. Inspired by a series of papers implicating MBL in the pathogenesis of ischemia/reperfusion injury in other organs [31] , two competing groups have recently published studies suggesting that MBL-mediated complement activation serves a deleterious role in stroke. First, Cervera et al. directly assessed the role of MBL in stroke using MBL-KO mice subjected to transient MCAO. This study revealed that genetic MBL deletion resulted in smaller infarcts and improved functional outcome when assessed at 48 h [13] . More recently, Morrison et al. also found that MBL-KO mice subjected to transient MCAO exhibited significant reductions in striatal injury relative to wild-type controls [14] . The authors of these studies imply that MBL may serve as an effective therapeutic target in stroke.
The present study provides further details regarding the temporal and spatial sequence of post-ischemic cerebral complement activation. Herein, we demonstrate that MBL is the first complement protein to bind to ischemic cerebral endothelium, where it co-localizes with both IgM and C3 as early as 0 h post-reperfusion. This study is also the first to provide evidence that IgM may be involved in the initiation of post-ischemic complement activation in the brain and that this initial interaction occurs at the ischemic endothelial surface. Whether IgM or MBL directly binds the putative neo-antigens presented by ischemic endothelium, as well as the specific identity of these antigens, however, remains to be elucidated. By comparison, no significant deposition of either factor B or C1q is observed at the same early time point, supporting a predominant role for MBL as the proximal mechanism of complement activation in the acute phase of stroke. By 24 h post-reperfusion, MBL-a convincingly co-localizes with neuronal-specific cellular markers in the ischemic region, while MBL-c remains restricted to the perivascular regions. This suggests that propagation of complement-mediated tissue injury likely involves damage and subsequent breakdown of the blood-brain barrier. Moreover, this differential pattern of staining suggests that MBL-a and MBL-c may serve distinct functions following cerebral ischemia, although this remains unproven.
Our data confirm a robust neuroprotective effect for genetic MBL deletion in the acute post-stroke period. However, as delineated by the STAIR criteria [32] , evaluation beyond the acute phase is essential to properly assess the efficacy of a candidate neuroprotective strategy. In fact, in the present study, mice genetically deficient in MBL do not exhibit improvements in either infarct volume or neurological function when examined at 7 days. This lack of neuroprotection occurs despite a reduction in C3a levels reflective of persistent suppression of downstream complement activation. Previous works by our group and others have demonstrated that C3a expression is associated with worse outcome secondary to increased granulocyte/ neutrophil infiltration into the ischemic region [5, 9] and that MBL inhibition suppresses acute inflammation through a reduction in neutrophil infiltration when assessed at an early time point [13] . The results of the present study suggest that MBL and downstream complement deposition may play a different role in ischemic injury at later time points.
At 7 days post-stroke, animals deficient in MBL exhibit a reduction in CD68-positive cells, which represent a predominant class of inflammatory cells present in the subacute infarct [33] . The persistent suppression of postischemic inflammation observed in the MBL-KO mice likely contributes to the loss of neuroprotection in the A B subacute period. For example, inflammatory cells, in particular activated microglia and infiltrating macrophages, are known to promote subacute post-ischemic repair both through phagocytosis of damaged cells as well as through the production of growth factors, such as the nerve growth factor and brain-derived neurotrophic factor, and antiinflammatory cytokines, such as interleukin-10 [34] . Future experiments will directly evaluate the neuroprotective mechanisms associated with MBL suppression in the later phases of stroke. Alternatively, it remains possible that genetic MBL deficiency simply delays the progression of ischemic injury, so that neuroprotection observed with early outcome assessment is not maintained at later time points. A third possibility is that complement itself, functioning either directly through MBL or through downstream effector components, may serve a beneficial function at later time points following cerebral I/R [35] . For instance, a recent work suggests a positive regulatory role for complement in ischemia-induced neurogenesis [18] . Furthermore, complement also functions in the clearance of apoptotic cells, and deposition of MBL as well as other downstream opsonins, such as C3b or C5b, may serve a protective role by clearing apoptotic cells or cellular debris in the subacute period [36] . Clearly, gene-deficient animals do not represent the ideal model to assess the functional effects of complement inhibition across time, as they manifest suppressed complement at all times in all cell types. These concepts are supported by a recent study by Rahpeymai et al., who found that C3-deficient mice subjected to MCAO exhibited larger infarct volumes when assessed at 7 days, despite a robust neuroprotection observed in these same mice when assessed at 24 h [9, 18] . Therefore, further experiments utilizing either conditional mutants or rationally targeted pharmacotherapy must be employed to dissect the multiple possible functional roles for MBL, as well as both its possible deleterious and beneficial effects, across the post-ischemic recovery period.
Conclusion
Careful analysis of the timing and localization of complement activation is critical to the development of effective anti-complement neuroprotective strategies for stroke. The present study delineates the temporal and spatial sequence of MBL deposition and downstream complement cleavage at early time points following cerebral ischemia. Given the rapid deposition of MBL, pharmacologic strategies of MBL inhibition may prove most successful with pre-ischemic dosing, such as with high-risk patients undergoing neurosurgical or interventional procedures involving cerebral revascularization and/or temporary occlusion. Additionally, the lack of neuroprotection observed when MBL inhibition is maintained for 7 days suggests that strategies targeting MBL, and complement in general, must be carefully temporally tailored in order to maximize inhibition of early deleterious inflammation while retaining or even augmenting beneficial inflammatory responses. Despite these caveats, rationally applied anti-complement therapeutic strategies remain promising in the treatment of post-ischemic cerebral reperfusion injury.
